24/7 Market News Snapshot 31 October, 2024 – EVOGENE LTD. (NASDAQ:EVGN)
DENVER, Colo., 31 October, 2024 (247marketnews.com) – (NASDAQ:EVGN) are discussed in this article.
Evogene Ltd. (EVGN) is witnessing a remarkable surge in market activity, currently trading at $3.635, representing a significant increase of 51.46% from its previous closing price of $2.400. This uptick is accompanied by a robust trading volume of 1.19 million shares, indicative of strong investor interest and market confidence. This momentum is likely fueled by recent strategic developments within the company that merit close monitoring.
Notably, Evogene has entered a transformative collaboration with Google Cloud, which aims to revolutionize the design and development of small molecules in the life sciences domain. This partnership will leverage Evogene’s innovative ChemPass AI technology in conjunction with Google Cloud’s powerful computational resources to create a state-of-the-art AI foundation model dedicated to generative small molecule design.
Through this collaboration, Evogene plans to harness Google Cloud’s Vertex AI, along with cutting-edge GPUs and extensive storage capabilities, to train its new model on a dataset of approximately 40 billion molecular structures. This advanced model is expected to significantly accelerate the identification and evaluation of novel small molecules applicable to drug development, sustainable agriculture, and various life science products, enhancing both the speed and accuracy of candidate generation.
Ofer Haviv, President and CEO of Evogene, articulated the importance of this partnership, stating, “Our collaboration with Google Cloud underscores our commitment to advancing innovation in computational predictive biology.” The anticipated breakthroughs from this initiative promise substantial benefits not only to Evogene but also to stakeholders within the pharmaceutical and agricultural sectors.
By synergizing Evogene’s expertise in computational biology with Google Cloud’s leading-edge AI tools, this partnership is set to reshape research and development efforts, aiding organizations in achieving a competitive advantage through advanced generative design capabilities. The industry is poised for groundbreaking advancements, positioning Evogene and Google Cloud at the forefront of innovation in life sciences.
Related news for (EVGN)
- Evogene Reports Second Quarter 2025 Financial Results
- Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
- Evogene Announces Completion of Transaction for the Sale of Lavie Bio’s Activity to ICL
- Closing Bell Buzz: Small Caps, Big Moves
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/10/25 07:00 AM